Global C-MET & HGF Inhibitors Market Growth 2025-2031

The global C-MET & HGF Inhibitors market size is predicted to grow from US$ 3435 million in 2025 to US$ 12970 million in 2031; it is expected to grow at a CAGR of 24.8% from 2025 to 2031.

c-Met inhibitors are a class of small molecules that inhibit the enzymatic activity of the c-Met tyrosine kinase, the receptor of hepatocyte growth factor/scatter factor (HGF/SF).

There are three kinds of C-MET / HGF Inhibitors, which are Cabozantinib, Crizotinib and Others. Cabozantinib hold the largest share of the C-MET / HGF Inhibitors market, with a revenue market share nearly 66% in 2019.

C-MET / HGF Inhibitors is sold through Hospitals and Drugs Store. The most proportion of C-MET / HGF Inhibitors is sold through Hospitals, and the market share in 2019 is about 77%.

North America is the largest consumption place, with a consumption market share nearly 60% in 2019. Following North America, Europe is the second largest consumption place with the consumption market share of about 34%.

Shandong Exelixis, Ipsen, Pfizer, etc. are the leader of the industry, and top 3 players hold about 100% revenue market share.

LP Information, Inc. (LPI) ' newest research report, the “C-MET & HGF Inhibitors Industry Forecast” looks at past sales and reviews total world C-MET & HGF Inhibitors sales in 2024, providing a comprehensive analysis by region and market sector of projected C-MET & HGF Inhibitors sales for 2025 through 2031. With C-MET & HGF Inhibitors sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world C-MET & HGF Inhibitors industry.

This Insight Report provides a comprehensive analysis of the global C-MET & HGF Inhibitors landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on C-MET & HGF Inhibitors portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global C-MET & HGF Inhibitors market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for C-MET & HGF Inhibitors and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global C-MET & HGF Inhibitors.

This report presents a comprehensive overview, market shares, and growth opportunities of C-MET & HGF Inhibitors market by product type, application, key manufacturers and key regions and countries.

Segmentation by Type:
Cabozantinib
Crizotinib
Others

Segmentation by Application:
Hospital
Drug Store

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
Exelixis
Ipsen
Pfizer
Novartis
Takeda
Merck KGaA
Merck
Daiichi Sankyo
GSK
Bristol-Myers Squibb(BMS)
Roche
AVEO Pharmaceuticals
Amgen
AstraZeneca
Mirati Therapeutics
Eli Lilly
Johnson & Johnson
Eisai
Hutchison MediPharma
Kringle Pharmaceuticals

Key Questions Addressed in this Report

What is the 10-year outlook for the global C-MET & HGF Inhibitors market?

What factors are driving C-MET & HGF Inhibitors market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do C-MET & HGF Inhibitors market opportunities vary by end market size?

How does C-MET & HGF Inhibitors break out by Type, by Application?

Please note: The report will take approximately 2 business days to prepare and deliver.